All News

Found 3,189 articles

• Adimab LLC. and Mersana Therapeutics, Inc. Announce Antibody-Drug Conjugate Alliance

  8/1/2012

• Mersana Therapeutics, Inc. Raises $27 Million to Advance Antibody-drug Conjugates

  7/31/2012

• EnVivo Pharmaceuticals, Inc.' Drug Helps Memory in Early Study

  7/23/2012

• Synthon Pharmaceuticals Enters Into Global License Agreement With Amgen and Watson Pharmaceuticals, Inc. for Biosimilar Trastuzumab

  7/18/2012

• ADC Therapeutics Appoints Former Genmab A/S VP Dr Patrick van Berkel as Senior VP of R&D

  7/17/2012

• Cytotoxic Warheads at Forefront of Cancer Research Technology, ADC Therapeutics' Anticancer Collaboration

  7/6/2012

• American Society of Clinical Oncology 2012: Show Me the Overall Survival Data!

  6/6/2012

• Esperance Pharmaceuticals, Inc. Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory LHRH-Receptor Expressing Solid Tumors at American Society of Clinical Oncology

  6/4/2012

• Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference

  5/18/2012

• Intellect Neurosciences, Inc. Expands Its Immunotherapy Pipeline with New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington's and Parkinson's Diseases

  5/17/2012

• Intellect Neurosciences, Inc. Adds Two New Tau Programs to its Alzheimer's Disease Development Pipeline

  5/8/2012

• Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland

  5/2/2012

• Celldex Therapeutics, Inc. Announces Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer

  5/1/2012

• Salix Pharmaceuticals, Ltd., Progen Pharmaceuticals Limited Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012

  4/25/2012

• Intellect Neurosciences, Inc. Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California, Irvine to Test First in Class Dual Target Vaccine

  4/17/2012

• Peregrine Pharmaceuticals, Inc. Launches PS-Targeting Clinical Imaging Program

  4/3/2012

• Roche's T-DM1: Triple Threat to Breast Cancer or Another Avastin Disaster?

  4/3/2012

• Esperance Pharmaceuticals, Inc. Presents Poster at American Association for Cancer Research Annual Meeting Demonstrating Synergy of Lead Candidate EP-100 with Paclitaxel in In Vitro Studies

  4/3/2012

• PolyTherics Announces a Research Collaboration With Spirogen Ltd. to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

  4/2/2012

• Celtic Therapeutics Pledges $50 Million to Establish ADC Therapeutics, New Company Will Develop Antibody-Drug Conjugates

  3/26/2012